BioCentury
ARTICLE | Emerging Company Profile

Engrail aims to build CNS pipeline by improving upon deprioritized assets

Nan Fung-backed Engrail to expand CNS pipeline starting with in-licensed GABA A modulator

July 1, 2020 4:11 PM UTC

With a $32 million series A round from Nan Fung, Engrail expects to advance its first CNS program into the clinic by 1Q21 as it builds out a pipeline of neuroscience drugs via deals for deprioritized assets.

Co-founded in 2019 by President and CEO Vikram Sudarsan and CSO and EVP of Development Stephen Cunningham, Engrail Therapeutics Inc. plans to in-license drugs with a validated mechanism of action or that have shown strong preclinical or clinical proof of concept...

BCIQ Target Profiles

GABA A receptor